Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion in Severe Osteoarthritis of the Knee
NCT03988023Phase 3Terminated
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of aspartyl-alanyl-diketopiperazine in knee osteoarthritis (OA), sponsored by Ampio Pharmaceuticals, Inc.. Started Jun 2019; status: terminated.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03988023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988023.